NASDAQ:IRMD - Iradimed Stock Price, News & Analysis

$21.13
+0.13 (+0.62 %)
(As of 08/18/2019 11:01 AM ET)
Today's Range
$20.97
Now: $21.13
$21.87
50-Day Range
$17.74
MA: $20.01
$23.97
52-Week Range
$16.68
Now: $21.13
$38.78
Volume49,500 shs
Average Volume94,915 shs
Market Capitalization$240.25 million
P/E Ratio49.14
Dividend YieldN/A
Beta1.65
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IRMD
CUSIPN/A
Phone407-677-8022

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.44 million
Cash Flow$0.5848 per share
Book Value$4.15 per share

Profitability

Net Income$6.30 million

Miscellaneous

Employees95
Market Cap$240.25 million
Next Earnings Date10/29/2019 (Estimated)
OptionableNot Optionable

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.


Iradimed (NASDAQ:IRMD) Frequently Asked Questions

What is Iradimed's stock symbol?

Iradimed trades on the NASDAQ under the ticker symbol "IRMD."

How were Iradimed's earnings last quarter?

Iradimed Corp (NASDAQ:IRMD) posted its quarterly earnings results on Tuesday, October, 30th. The medical equipment provider reported $0.14 EPS for the quarter, beating the Zacks' consensus estimate of $0.10 by $0.04. The medical equipment provider earned $7.62 million during the quarter, compared to the consensus estimate of $7.43 million. Iradimed had a return on equity of 14.78% and a net margin of 23.92%. View Iradimed's Earnings History.

When is Iradimed's next earnings date?

Iradimed is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Iradimed.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its third quarter 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $0.14-0.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.16. The company issued revenue guidance of $9.7-10 million, compared to the consensus revenue estimate of $9.84 million.

What price target have analysts set for IRMD?

1 analysts have issued 12 month price objectives for Iradimed's shares. Their predictions range from $35.00 to $35.00. On average, they anticipate Iradimed's share price to reach $35.00 in the next year. This suggests a possible upside of 65.6% from the stock's current price. View Analyst Price Targets for Iradimed.

What is the consensus analysts' recommendation for Iradimed?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.

Has Iradimed been receiving favorable news coverage?

News articles about IRMD stock have trended negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iradimed earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Iradimed.

Are investors shorting Iradimed?

Iradimed saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 457,700 shares, a decrease of 13.2% from the June 30th total of 527,200 shares. Based on an average daily trading volume, of 78,800 shares, the short-interest ratio is currently 5.8 days. Approximately 9.3% of the shares of the company are sold short. View Iradimed's Current Options Chain.

Who are some of Iradimed's key competitors?

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), Palo Alto Networks (PANW), BioTelemetry (BEAT), Alphabet (GOOG), Micron Technology (MU), CVS Health (CVS), GrubHub (GRUB), Mastercard (MA) and IntriCon (IIN).

Who are Iradimed's key executives?

Iradimed's management team includes the folowing people:
  • Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Christopher K. Scott, CFO & Sec. (Age 49)
  • Mr. John McCreery, Chief Operating Officer (Age 64)
  • Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
  • Mr. Louis Waldman, Controller (Age 64)

Who are Iradimed's major shareholders?

Iradimed's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Atria Investments LLC (6.92%), BlackRock Inc. (3.44%), Renaissance Technologies LLC (3.20%), Vanguard Group Inc. (2.43%), RK Capital Management LLC (1.70%) and Mondrian Investment Partners LTD (1.47%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.

Which major investors are selling Iradimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Acadian Asset Management LLC, Victory Capital Management Inc., Cadence Capital Management LLC, LPL Financial LLC, GSA Capital Partners LLP, Fiera Capital Corp and Wells Fargo & Company MN. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Francis X Casey, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.

Which major investors are buying Iradimed stock?

IRMD stock was acquired by a variety of institutional investors in the last quarter, including Atria Investments LLC, Marshall Wace LLP, RK Capital Management LLC, BlackRock Inc., Mondrian Investment Partners LTD, Renaissance Technologies LLC, Bank of New York Mellon Corp and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Iradimed.

How do I buy shares of Iradimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Iradimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $21.13.

How big of a company is Iradimed?

Iradimed has a market capitalization of $240.25 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.View Additional Information About Iradimed.

What is Iradimed's official website?

The official website for Iradimed is http://www.iradimed.com/.

How can I contact Iradimed?

Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]


MarketBeat Community Rating for Iradimed (NASDAQ IRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  208 (Vote Underperform)
Total Votes:  414
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel